



April 5, 2016

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center - WO66-G609
Silver Spring, MD 20993-0002

Olympus, Winter & Ibe GmbH
% Ms. Sheri L. Musgnung
Manager, Regulatory Affairs
Olympus Corporation of the Americas
3500 Corporate Parkway
Center Valley, Pennsylvania 18034

Re: K153009

Trade/Device Name: Ultra Telescopes
Regulation Number: 21 CFR 874.4760
Regulation Name: Nasopharyngoscope (Flexible Or Rigid) And Accessories
Regulatory Class: Class II
Product Code: EOB
Dated: March 4, 2016
Received: March 7, 2016

Dear Ms. Musgnung:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"

(21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,


Denise L. Hampton -S

for Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic and Ear,

Nose and Throat Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K153009

Device Name

"ULTRA" Telescopes

Indications for Use (Describe)

Telescope for endoscopic observation, diagnosis and treatment during nasal endoscopy and sinuscopy.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary of Safety and Effectiveness

October 12, 2015

1. General information

- Manufacturer/Holder Olympus Winter & Ibe GmbH
Kuehnstr. 61
22045 Hamburg
Germany
- Establishment Registration No.: 9610773
- Official Correspondent: Sheri L. Musgnung
Regulatory Affairs & Quality Assurance
Olympus Corporation of the Americas
3500 Corporate Parkway
PO Box 610
Center Valley, PA 18034-0610
Phone: 484-896-3147
FAX: 484-896-7128
Email: sheri.musgnung@olympus.com
Establishment Registration No.: 2429304

2. Device identification

- Proprietary name: "ULTRA" Telescopes
- Common name: Sinusscopes
- Regulation Number: 21 CFR 874.4760
- Regulation Description: Nasopharyngoscope (flexible or rigid) and
Accessories
- Device Class: II
- Product Code: EOB
- Review Panel: Ear Nose & Throat

3. Predicate device

K944072, Olympus Nasal & Sinus Endoscopes

4. Description of device

The “ULTRA” Telescopes are rigid endoscopes. An image relay system of rod lenses transmits the endoscopic image. A bundle of optical fibers transmits light from an external light source to illuminate the endoscopic image.

The “ULTRA” Telescopes are delivered non-sterile. They are reusable and fully autoclavable. Before first and each subsequent use the device must be inspected and reprocessed according to defined reprocessing methods in the Instructions for Use.

The “ULTRA” Telescopes are available with four different directions of view (0°, 30°, 45°, and 70°) to allow use for various applications in accordance with the intended use as submitted with this 510(k). To address surgeon’s preferences, the 30°, 45°, and 70° models are available as an inverse version as well (the light guide cable adapter is at the bottom, instead of at the top of the telescope).

5. Indications of use

Telescope for endoscopic observation, diagnosis and treatment during nasal endoscopy and sinuscopy.

6. Comparison of Technological characteristics

The subject and predicate devices are based on the same technological principles:

- Rigid endoscopes consisting of insertion tube, rod-lens and light-guide system, connector and eyepiece cup. The predicate device additionally had a locking cone for sheath connection.
- A bundle of optical fibers transmits light from an external light source to illuminate the endoscopic image
- The image relay system of rod lenses transmits the endoscopic image
- Identical insertion portion width and optical system diameter
- Maximum working length of subject device is slightly longer
- Identical Direction of Views (DOVs)
- The Field of View (FOV) of the subject devices has been decreased by 2°
- The same patient contacting materials are used in the predicate and subject device

7. Performance Data

Risk analysis was carried out in accordance with established in-house acceptance criteria based on ISO-14971:2007.

Performance tests were carried out to ensure that the system functions as intended and meets design specifications. The following performance tests and usability studies were conducted:

Biocompatibility testing

The biocompatibility evaluation for the subject device was conducted in accordance with the FDA Blue Book Memorandum #G95-1 "Use of International Standard ISO-10993, 'Biological Evaluation of Medical Devices Part 1: Evaluation and Testing,'" May 1, 1995.

The testing included the following tests:

- Biological Safety – toxicology: AAMI ANSI ISO 10993-1:2009; Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing within a Risk Management Process
- Cytotoxicity: AAMI ANSI ISO 10993-5:2009; Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity
- Chemical Analysis: AAMI ANSI ISO 10993-12:2012; Biological evaluation of medical devices - Part 12: Sample Preparation and Reference Materials

Electrical safety and electromagnetic compatibility (EMC)

Electrical Safety was tested according to AAMI/ANSI ES 60601-1:2005 and C1:2009 and A2:2010; Medical Electrical Equipment - Part 1.1 General requirements for safety and essential performance.

Electromagnetic compatibility (EMC) is not applicable. The devices are not electrically powered and are just used with light from a light source.

Thermal Safety

Tested according to IEC 60601-2-18:2009, Medical electrical equipment - Part 2-18: IEC 60601-2-18 Edition 3.0 2009-08, medical electrical equipment - part 2-18: Particular requirements for the basic safety and essential performance of endoscopic equipment.

Performance Testing Bench

Conducted tests cover optical and mechanical performance testing, shipping tests, tests related to the expected service life and testing of the illumination system. Additionally, design validation/usability tests were conducted.

The following standards have been applied to the “ULTRA” Telescopes:

Rec. No. Standard

19-5	AAMI / ANSI ES60601-1: 2005/(R)2012 and C1:2009/(R)2012
9-61	IEC 60601-2-18:2009
5-89	IEC 60601-1-6:2013
9-83	ISO 8600-1:2013
9-84	ISO 8600-3:1997 + AM1(2003)
9-94	ISO 8600-4:2014
9-39	ISO 8600-5:2005
9-40	ISO 8600-6:2005
2-156	AAMI ANSI ISO 10993-1: 2009
2-153	AAMI ANSI ISO 10993-5: 2009
2-191	ISO 10993-12: 2012
5-40	ISO 14971:2007
14-333	ISO 17665-1:2006

8 Conclusions

The performance data support the safety of the device and demonstrate that the subject devices comply with the intended use as specified.

In summary, we believe the “ULTRA” Telescopes are substantially equivalent to the predicate devices with respect to the general design approach, function, and the intended use. The “ULTRA” Telescopes raise no new concerns of safety or effectiveness compared to the predicate devices.